Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran

Pharmacological Reports

Volumn 62, Issue 4, 2010, Pages 740-746

  Azarpira, Negar ^a   Namazi, Soha ^b   Hendijani, Fatemeh ^b   Banan, Maryam ^b   Darai, Masumeh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CYP2C19; CYP2C9; Genotype; Iranian; VKORC1

Indexed keywords

ADENINE; GUANINE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; CHINESE; CONTROLLED STUDY; CYP2C19 GENE; CYP2C9 GENE; DNA POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; IRAN; JAPANESE; MALE; PHARMACOGENETICS; POPULATION GENETICS; VKORC1 GENE;

EID: 77958007990     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70332-7     Document Type: Article

References (30)

1. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R: Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol, 2003, 59, 707-709.
2. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG: Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol, 2007, 21, 419-426.
3. Bertilsson L, Dahl ML, Ingelman-Sundberg M, Johansson I, Sjoqvist F: Inter-individual and inter-ethnic differences in polymorphic drug oxidation. Implication for drug therapy with focus on psychoactive drugs. In: Advanced in drug metabolism in man. Eds. Pacifici GM, Fracchia GN, European Communities, Bruxelles, 1995, 86-136.
4. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M: A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood, 2005, 105, 645-649.
5. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol, 1994, 46, 594-598.
6. Farjadian S, Ghaderi A: HLA class II genetic diversity in Arabs and Jews of Iran. Iran J Immunol, 2007, 4, 85-93.
7. Farjadian S, Ghaderi A: HLA class II similarities in Iranian Kurds and Azeris. Int J Immunogenet, 2007, 34, 457-463.
8. Farjadian S, Naruse T, Kawata H, Ghaderi A, Bahram S, Inoko H: Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. Tissue Antigens, 2004, 64, 581-587.
9. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T et al.: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol, 2003, 59, 303-312.
10. Goldstein JA, de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 1994, 4, 285-299.
11. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol, 2002, 53, 596-603.
12. Herman D, Dolzan V, Breskvar K. Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. Zdrav Vestn, 2003, 72, 347-351.
13. http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9934438.
14. Isaza C, Henao J, Martínez JH, Arias JC, Beltrán L: Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol, 2007, 7, 6.
15. Lamba JK, Dhiman RK, Kohli KK: CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther, 2000, 68, 328-335.
16. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature, 2004, 5, 541-544.
17. Meyer UA: The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol, 1994, 46, Suppl, 409-415.
18. Miao L, Yang J, Huang C, Shen Z: Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol, 2007, 63, 1135-1141.
19. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol, 1998, 45, 525-538.
20. Moridani M, Fu L, Selby R, Yun F, Sukovic T, Wong B, Cole DE: Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin Biochem, 2006, 39, 606-612.
21. Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, Shimomura H et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet, 2006, 51, 249-253.
22. Pang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC: Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58, 332-335.
23. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type2. Nature, 2004, 427, 537-541.
24. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106, 2329-2333.
25. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res, 2004, 50, 195-200.
26. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B et al.: Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem, 2004, 50, 1623-1633.
27. Taube J, Halsall D, Baglin T: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96, 1816-1819.
28. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R et al.: Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J, 1993, 289, 533-538.
29. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun, 1999, 254, 628-631.
30. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34, 102-105.